IntegraGen OncoDNA to Widen Cancer Analytics Offering, Biopharma Reach With IntegraGen Acquisition Premium Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians. OncoDNA to Acquire IntegraGen for €14.5M Belgium-based OncoDNA will purch IntegraGen Receives CE Mark, Installs Software at Dana-Farber Cancer Institute Premium The French bioinformatics and genomic services company will help Dana-Farber manage French Medical Genomics Initiative's Pilot Sequencing Platforms Set to Commence Operations Premium The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago. GoPath Labs to Commercialize IntegraGen Cancer Therapy Biomarker Test GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker. Sep 7, 2017 IntegraGen Theranostic Test for Colorectal Cancer Gets CE-IVD Mark Mar 8, 2017 IntegraGen, Laboratoire Cerba Ink Cancer Biomarker Deal Jul 1, 2016 Paris University Hospitals, IntegraGen Partner to Develop Sequencing Platform Dec 2, 2015 IntegraGen Partners With FIRE-3 Researchers to Study microRNA Cancer Biomarker Jul 9, 2015 IntegraGen, Pompidou Hospital to Develop Sequencing Methods Mar 24, 2015 IntegraGen to Provide High-throughput Sequencing for Institut Pasteur Feb 5, 2015 Genoma to Commercialize IntegraGen ASD Test Dec 16, 2014 IntegraGen, PICCOLO Researchers Collaborate to Validate Metastatic Colorectal Cancer Biomarker Dec 8, 2014 IntegraGen Nets Exclusive Rights to Liver Cancer Gene Signatures Sep 3, 2014 IntegraGen, IFCT to Evaluate microRNA as Lung Cancer Biomarker Jun 23, 2014 French Consortium Launches Clinical Exome Interpretation Project for Cancer Patients Apr 23, 2014 Gustave Roussy, IntegraGen Partner to Support Clinical Cancer Trials with Exome, RNA Sequencing Premium Mar 24, 2014 IntegraGen, Gustave Roussy Create Clinical Sequencing Unit Jan 14, 2014 IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response Oct 17, 2013 IntegraGen Prepping miRNA-based Colorectal Cancer Assay for CE Mark; Exploring CLIA Options for US Premium Oct 17, 2013 After Licensing microRNA IP, IntegraGen Aims to Launch Cancer Diagnostic in '14 Premium Oct 14, 2013 IntegraGen Acquires Exclusive License to Metastatic Colon Cancer Biomarker Feb 28, 2013 Lab21, IntegraGen to Develop PCR-Based Assay to Guide Colorectal Cancer Therapy Premium Feb 28, 2013 Lab21 to Develop microRNA-Based Colorectal Cancer Diagnostic for IntegraGen Premium Feb 22, 2013 Lab21, IntegraGen Co-developing CDx for Colorectal Cancer Therapy Load More Breaking News People in the News at Probius, Flagship Biosciences, Discovery Life Sciences, More New Products Posted to GenomeWeb: BillionToOne, Becton Dickinson, Enzo Biochem, More Stroke Risk Contributors, Treatment Targets Uncovered in Cross-Ancestry GWAS In Brief This Week: Yourgene Health, Bionano Laboratories, Caris Life Sciences, More Enzymatic RNA Synthesis Firm EnPlusOne Biosciences Launches With $12M in Seed Funding The Scan Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says. Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds. Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry. UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.